412327-07-2

Basic information

• Product Name: 4-Methoxybenzylhydrazine dihydrochloride
• Synonyms: (4-Methoxyphenyl)Methyl]-hydrazine dichlorhydrate;[(4-methoxyphenyl)methyl]hydrazine dihydrochloride;1-(4-Methoxybenzyl)hydrazine dihydrochloride;Hydrazine, [(4-methoxyphenyl)methyl]-, hydrochloride (1:2);(4-METHOXYBENZYL)HYDRAZINE HCL;(4-METHOXYBENZYL)HYDRAZINE 2HCL
• CAS NO: 412327-07-2
• Molecular Formula: C8H14Cl2N2O
• Molecular Weight: 225.11556
• Mol File: 412327-07-2.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 4-Methoxybenzylhydrazine dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxybenzylhydrazine dihydrochloride(412327-07-2)
• EPA Substance Registry System: 4-Methoxybenzylhydrazine dihydrochloride(412327-07-2)

Safety Data

• Hazardous Substances Data: 412327-07-2(Hazardous Substances Data)

Usage

Uses

(4-Methoxybenzyl)hydrazine Dihydrochloride is used in preparation of Heterocyclic derivatives useful as SHP2 inhibitors.

Upstream product

• 824-94-2 p-methoxybenzyl chloride 
• 123-11-5 4-methoxy-benzaldehyde 
• 150767-02-5 N-1-(tert-butoxycarbonyl)-N-2-<(4-methoxyphenyl)methyl>hydrazine 

Downstream Products

• 1152526-72-1 1-(4-methoxybenzyl)-4-methyl-1H-pyrazol-5-amine 
• 949556-61-0 1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-amine 

Relevant articles and documents

6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE

The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Development and a practical synthesis of the JAK2 inhibitor LY2784544

The route selection and process research and development of a practical synthesis for JAK2 inhibitor LY2784544 is described. The first-generation synthesis route, similar to that used in discovery for derivatization of a benzylic amine moiety, was 14 overall steps and possessed several steps that required extensive development for large-scale production. Route selection considerations led to a modified synthesis that utilized a novel vanadium-catalyzed carbon-carbon bond-forming arylation reaction for incorporation of the key benzylic morpholine moiety. A protecting group used to mask an amino pyrazole unit was modified from PMB to tert-butyl, resulting in a dramatic reduction in the overall length of the route. These two major changes resulted in an eight-step synthesis, which was six steps shorter than the first-generation synthesis. In the pilot plant, the new synthesis was scaled to produce >100 kg of LY2784544 in high yield and purity under GMP conditions. The overall development including the vanadium-catalyzed C-C bond-forming methodology, a ketone reductive deoxygenation, and a palladium-catalyzed amination is described.